Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
273.3 AUD | -1.85% | +1.41% | -4.66% |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 49.23 and 40.94 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.66% | 87.53B | A- | ||
+2.63% | 40.42B | A- | ||
-21.76% | 29.48B | B- | ||
+56.27% | 25.43B | A | ||
-14.78% | 15.59B | C | ||
-18.49% | 11.49B | B- | ||
-15.61% | 11.1B | D+ | ||
-44.02% | 11.3B | B | ||
+0.97% | 8.75B | B+ | ||
-8.42% | 7.99B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CSL Stock
- Ratings CSL Limited